Keyphrases
Hepatocellular Carcinoma
75%
Pancreatic Cancer
56%
Confidence Interval
39%
Odds Ratio
21%
Overall Survival
20%
Advanced Hepatocellular Carcinoma
18%
Risk Factors
15%
Pancreatic Cancer Risk
13%
Cancer Cases
13%
Hepatocellular Carcinoma Risk
12%
Genotype
11%
Hepatocellular Carcinoma Patients
11%
Diabetes
10%
United States
9%
Adjusted Odds Ratio
9%
Genome-wide Association Study
8%
Pancreatic Ductal Adenocarcinoma
8%
Bevacizumab
8%
Insulin-like
8%
Progression-free Survival
8%
Growth Factors
7%
Clinical Significance
7%
Prognostic Biomarker
7%
Cancer Patients
6%
Polymorphism
6%
Log-rank Test
6%
Tumor
6%
Phase II Trial
6%
Liver Transplantation
6%
Unresectable Hepatocellular Carcinoma
6%
Sorafenib
6%
Single nucleotide Polymorphism
5%
Vascular Endothelial Growth Factor
5%
MD Anderson Cancer Center
5%
Excessive Drinking
5%
Gene Polymorphism
5%
Median Overall Survival
5%
Cigarette Smoking
5%
Metformin
5%
Clinical Outcomes
5%
Risk Loci
5%
Hospital-based Case-control Study
5%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Pancreas Cancer
38%
Malignant Neoplasm
27%
Overall Survival
23%
Odds Ratio
22%
Case-Control Study
19%
Biological Marker
16%
Diseases
13%
Neoplasm
12%
Liver Cirrhosis
12%
Liver Transplantation
11%
Diabetes
10%
Somatomedin C
10%
Neuroendocrine Tumor
10%
Hepatitis C Virus
10%
Genome Wide Association Study
9%
Vasculotropin
8%
Cholangiocarcinoma
8%
Diabetes Mellitus
8%
Alcohol Consumption
7%
Cancer Risk
7%
Scoring System
7%
Fluorouracil
6%
Hepatitis B Virus
6%
Child-Pugh Score
6%
Liver Cancer
6%
Progression Free Survival
6%
Hazard Ratio
6%
Cancer
5%
Transcatheter Arterial Chemoembolization
5%
Cohort Effect
5%
Smoking
5%
Logistic Regression Analysis
5%
Glycon
5%
Cancer Diagnosis
5%
Proportional Hazards Model
5%
Nonalcoholic Fatty Liver
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
86%
Pancreas Cancer
36%
Malignant Neoplasm
24%
Overall Survival
21%
Case-Control Study
18%
Neoplasm
14%
Biological Marker
12%
Phase II Trials
10%
Diseases
9%
Progression Free Survival
9%
Hepatitis C Virus
8%
Bevacizumab
8%
Sorafenib
8%
Liver Cancer
7%
Diabetes Mellitus
7%
Mutagenic Agent
6%
Vasculotropin
6%
Acyltransferase
6%
Cytochrome
6%
Hepatitis C
5%
Hepatitis B Virus
5%
Metformin
5%
Recurrent Disease
5%